Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Nurix Therapeutics stock

Own Nurix Therapeutics stock in just a few minutes.

Nurix Therapeutics, Inc is a biotechnology business based in the US. Nurix Therapeutics shares (NRIX) are listed on the NASDAQ and all prices are listed in US Dollars. Nurix Therapeutics employs 135 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Nurix Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NRIX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Nurix Therapeutics share price

Use our graph to track the performance of NRIX stocks over time.

Nurix Therapeutics shares at a glance

Information last updated 2021-04-21.
52-week range$15.21 - $51.46
50-day moving average $33.78
200-day moving average $35.06
Wall St. target price$48.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.82

Buy Nurix Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Nurix Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nurix Therapeutics financials

Revenue TTM $20 million
Gross profit TTM $-48,674,000
Return on assets TTM -19.82%
Return on equity TTM -44.36%
Profit margin -276.09%
Book value N/A
Market capitalisation $1.3 billion

TTM: trailing 12 months

Shorting Nurix Therapeutics shares

There are currently 4.3 million Nurix Therapeutics shares held short by investors – that's known as Nurix Therapeutics's "short interest". This figure is 60.3% up from 2.7 million last month.

There are a few different ways that this level of interest in shorting Nurix Therapeutics shares can be evaluated.

Nurix Therapeutics's "short interest ratio" (SIR)

Nurix Therapeutics's "short interest ratio" (SIR) is the quantity of Nurix Therapeutics shares currently shorted divided by the average quantity of Nurix Therapeutics shares traded daily (recently around 739676.41025641). Nurix Therapeutics's SIR currently stands at 5.85. In other words for every 100,000 Nurix Therapeutics shares traded daily on the market, roughly 5850 shares are currently held short.

However Nurix Therapeutics's short interest can also be evaluated against the total number of Nurix Therapeutics shares, or, against the total number of tradable Nurix Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nurix Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Nurix Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.1395% of the tradable shares (for every 100,000 tradable Nurix Therapeutics shares, roughly 140 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Nurix Therapeutics.

Find out more about how you can short Nurix Therapeutics stock.

Nurix Therapeutics share dividends

We're not expecting Nurix Therapeutics to pay a dividend over the next 12 months.

Nurix Therapeutics overview

Nurix Therapeutics, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; DeTIL-0255 for tumor infiltrating lymphocytes therapy; KINASE-CTM3 to treat T cell malignancies and autoimmune diseases; and LIGASE-INH2 for immuno-oncology. In addition, the company develops programs, such as COVID-CTM1, COVID-CTM2, and COVID-CTM3 that are designed for protein degradation to SARs CoV2 targets. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site